专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006028269A2 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY 审中-公开
标题翻译：具有VAP-1抑制活性的噻唑衍生物
公开(公告)号：WO2006028269A2
公开(公告)日：2006-03-16
申请号：PCT/JP2005/016984
申请日：2005-09-08
申请人： Astellas Pharma Inc. , INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
发明人： INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
IPC分类号： C07D417/06 , A61K31/427 , A61P27/02 , C07D277/46 , A61K31/426 , C07D417/10 , C07D417/12
CPC分类号： C07D417/10 , C07D277/46 , C07D417/06 , C07D417/12
摘要： A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is -CONH- or -NR 1 CO- wherein R 1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: or wherein R 2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, -NH- or ; D is a bond, -CS- or -CO-; E is a bond or -NH-; F is a bond, -CO-, -O- or -SO 2 -; and G is lower alkyl, optionally protected amino, -OH, phenyl, or ; and R 3 is lower alkyl, provided that when Z is a group of the formula: , then G should not be amino, when Z is a group of the formula: , then G should not be , when Z is a group of the formula: and G is optionally protected amino, then D should be -CS-, or then A should be lower alkylene, B or E should be -NH- and F should be -CO-; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
摘要翻译：式（I）的化合物：U-V-W-X-Y-Z（I）其中U是低级烷基; V是-CONH-或-NR 1 CO-，其中R 1是氢或低级烷基; W是键或低级亚烷基; X是衍生自任选取代的噻唑的二价残基; Y是键或低级亚烷基; 并且Z是下式的基团：或其中R 2是下列基团：-A-B-D-E-F-G其中A是键或低级亚烷基; B是一个键，-NH-或; D是键，-CS-或-CO-; E是键或-NH-; F是键，-CO - ， - O-或-SO 2 - 。且G为低级烷基，任选保护的氨基，-OH，苯基或并且R 3为低级烷基，条件是当Z为下式基团时，则当Z为下式基团时，G不应为氨基，则G不应为 Z是下式的基团：G是任选保护的氨基，则D应为-CS-，或者A应为低级亚烷基，B或E应为-NH-，F应为-CO-; 或其药学上可接受的盐可用作血管粘附蛋白-1（VAP-1）抑制剂，以及用于预防或治疗VAP-1相关疾病，特别是黄斑水肿的药物组合物和方法，该方法包括施用有效的化合物或其药学上可接受的盐对受试者的量等。

2. 发明申请

WO2006011631A3 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY 审中-公开
公开(公告)号：WO2006011631A3
公开(公告)日：2006-02-02
申请号：PCT/JP2005/014136
申请日：2005-07-27
申请人： ASTELLAS PHARMA INC. , INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
发明人： INOUE, Takayuki , TOJO, Takashi , MORITA, Masataka
IPC分类号： C07D277/46 , A61K31/426
摘要： A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification,or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

3. 发明申请

WO2003082265A2 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING VIRUS INFECTIOUS DISEASES 审中-公开
标题翻译：用于治疗或预防病毒感染性疾病的药物组合物
公开(公告)号：WO2003082265A2
公开(公告)日：2003-10-09
申请号：PCT/JP2003/003929
申请日：2003-03-28
申请人： FUJISAWA PHARMACEUTICAL CO., LTD. , INOUE, Takayuki , MAKI, Katsuyuki , HATAKENAKA, Kazuaki , YAMAGISHI, Yukiko
发明人： INOUE, Takayuki , MAKI, Katsuyuki , HATAKENAKA, Kazuaki , YAMAGISHI, Yukiko
IPC分类号： A61K31/352
CPC分类号： A61K31/055 , A61K31/085 , A61K31/403 , A61K31/404 , A61K31/4184 , A61K31/437 , A61K31/472 , A61K31/517
摘要： This invention provides pharmaceutical compositions for treating or preventing virus infectious diseases, particularly caused by viruses belonging to Flaviviridae family.

4. 发明申请

WO2003057722A3 CYCLIC TETRAPEPTIDE COMPOUND AND USE THEREOF 审中-公开
公开(公告)号：WO2003057722A3
公开(公告)日：2003-07-17
申请号：PCT/JP2002/013754
申请日：2002-12-27
申请人： FUJISAWA PHARMACEUTICAL CO., LTD. , SATOH, Shigeki , URANO, Yasuharu , OSODA, Kazuhiko , HOSAKA, Mitsuru , SAWADA, Kozo , INOUE, Takayuki , MORI, Hiroaki , TAKAGAKI, Shoji , FUJIMURA, Takao , MATSUOKA, Hideaki , YOSHIZAWA, Katsuhiko
发明人： SATOH, Shigeki , URANO, Yasuharu , OSODA, Kazuhiko , HOSAKA, Mitsuru , SAWADA, Kozo , INOUE, Takayuki , MORI, Hiroaki , TAKAGAKI, Shoji , FUJIMURA, Takao , MATSUOKA, Hideaki , YOSHIZAWA, Katsuhiko
IPC分类号： C07K5/12
摘要： A cyclic tetrapeptide compound of the formula (I): wherein R 1 is hydrogen; R 2 is lower alkyl, aryl, optionally substituted ar(lower)alkyl, heterocyclic(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, lower alkylcarbamoyl(lower)alkyl or arylcarbamoyl(lower)alkyl; R 3 and R 4 are each independently hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, optionally substituted heterocyclic(lower)alkyl or cyclo(lower)alkyl(lower)alkyl, or R 3 and R 4 are linked together to form lower alkylene or condensed ring, or one of R 3 and R 4 is linked to the adjacent nitrogen atom to form a ring; R 5 is lower alkylene or lower alkenylene, Y is [wherein R Y1 is hydrogen, halogen or optionally protected hydroxy, R Y2 is hydrogen, halogen, lower alkyl or phenyl, and R Y3 is hydrogen or lower alkyl]; R 8 is hydrogen or lower alkyl; and n is an integer of 1 or 2, or a salt thereof.

5. 发明申请

WO9616981A3 PEPTIDE COMPOUNDS FOR PREVENTION AND/OR TREATMENT OF NO-MEDIATED DISEASES 审中-公开
标题翻译：用于预防和/或治疗无介入性疾病的肽类化合物
公开(公告)号：WO9616981A3
公开(公告)日：1996-09-06
申请号：PCT/JP9502428
申请日：1995-11-29
申请人： FUJISAWA PHARMACEUTICAL CO , ITOH YOSHIKUNI , IWAMOTO TOSHIRO , YATABE TAKUMI , HAMASHIMA HITOSHI , INOUE TAKAYUKI , HASHIMOTO SEIJI , OKU TERUO
发明人： ITOH YOSHIKUNI , IWAMOTO TOSHIRO , YATABE TAKUMI , HAMASHIMA HITOSHI , INOUE TAKAYUKI , HASHIMOTO SEIJI , OKU TERUO
IPC分类号： A61K38/00 , A61P3/08 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P13/02 , A61P15/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P43/00 , C07K5/06 , C07K5/065 , C07K5/068 , C07K5/072 , C07K5/078 , A61K38/05
CPC分类号： C07K5/06078 , A61K38/00 , C07K5/06043 , C07K5/0606 , C07K5/06086 , C07K5/06095 , C07K5/06104 , C07K5/06113 , C07K5/06139 , C07K5/06147
摘要： New peptide compounds of formula (I) wherein W is a group of formula (a) [in which R is hydrogen, halogen, lower alkyl, etc., Q is CH or N, L is a bivalent radical (b) (in which Y is CH or N, Z is NH, O or S, and --- is a single bond or a double bond), etc.,], etc., A is lower alkylene, -NHCO-, (c) (in which V is O or S), or -SO2-, T is hydrogen, aryl which may have suitable substituent(s), heterocyclic group, hydroxy, etc., A is lower alkylene, R is hydrogen or lower alkyl, etc., R is hydrogen, aryl which may have suitable substituent(s), hydroxy, protected hydroxy, etc., A is bond or lower alkylene, R is hydrogen or lower alkyl, etc., and R is carboxy, protected carboxy, heterocycliccarbonyl which may have suitable substituent(s), or a group of formula (d) (in which R is hydrogen or lower alkyl, and R is hydrogen, aryl, ar(lower)alkyl which may have suitable substituent(s), etc.), etc., and a pharmaceutically acceptable salt thereof which are useful as a medicament. 00000
摘要翻译：式（I）的新的肽化合物，其中W是式（a）的基团[其中R 1是氢，卤素，低级烷基等，Q是CH或N，L是二价基团（b）（其中Y是CH或N，Z是NH，O或S，并且 - 是单键或双键）等，等等，A 1，是低级亚烷基，-NHCO-，（c）（其中V是O或S）或-SO 2 - ，T是氢，可以具有合适取代基的芳基，杂环基，羟基等， 2>是低级亚烷基，R 8是氢或低级烷基等，R 3是氢，可具有合适取代基的芳基，羟基，保护的羟基等，A 3是键或低级亚烷基，R 9是氢或低级烷基等，R 4是羧基，被保护的羧基，可具有合适取代基的杂环羰基或式（d）的基团（其中R 5是氢或低级烷基，R 6是可具有合适取代基的氢，芳基，芳基（低级）烷基等）及其药学上可接受的盐，其用途 ul作为药物。 00000

6. 发明申请

WO1996013485A1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS 审中-公开
标题翻译：吡咯烷酮，喹啉和熔融N-酰基转移酶作为BRADYKININ拮抗剂
公开(公告)号：WO1996013485A1
公开(公告)日：1996-05-09
申请号：PCT/JP1995002192
申请日：1995-10-25
申请人： FUJISAWA PHARMACEUTICAL CO., LTD. , OKU, Teruo , KAYAKIRI, Hiroshi , SATOH, Shigeki , ABE, Yoshito , SAWADA, Yuki , INOUE, Takayuki , TANAKA, Hirokazu
发明人： FUJISAWA PHARMACEUTICAL CO., LTD.
IPC分类号： C07D215/16
CPC分类号： C07D401/12 , C07D215/26 , C07D215/40 , C07D215/42 , C07D215/48 , C07D241/40 , C07D401/14 , C07D403/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
摘要： The invention relates to Pyridopyrimidones, Quinolines and fused N-heterocyclic compounds of formula (I) wherein Z is a group of the formula (a) or (b) in which X is N or C-R , X is N or C-R , X is N or C-R , R is lower alkyl, R is hydrogen, lower alkyl, etc., R is hydrogen or lower alkyl, R is halogen, etc., R is halogen, etc., R is a group of formula (c), etc., A is lower alkylene, and Y is O, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.
摘要翻译：本发明涉及式（I）的吡啶并嘧啶酮，喹啉和稠合的N-杂环化合物，其中Z是式（a）或（b）的基团，其中X 1是N或CR 1，X 2 >为N或CR 9，X 3为N或CR 2，R 1为低级烷基，R 2为氢，低级烷基等，R 9为氢或低级烷基，R 3为卤素等，R 4为卤素等，R 5为式（c）等基团，A为低级亚烷基，Y为O等。及其药学上可接受的盐，其制备方法，涉及含有该组合物的药物组合物，以及在预防和/或治疗缓激肽或其类似物介导的人或动物疾病中的治疗方法。

7. 发明申请

WO1993016071A1 HETEROCYCLIC DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS 审中-公开
标题翻译：杂环衍生物作为ANGIOTENSIN II拮抗剂
公开(公告)号：WO1993016071A1
公开(公告)日：1993-08-19
申请号：PCT/JP1993000133
申请日：1993-02-03
申请人： FUJISAWA PHARMACEUTICAL CO., LTD. , OKU, Teruo , SETOI, Hiroyuki , KAYAKIRI, Hiroshi , SATOH, Shigeki , INOUE, Takayuki , SAWADA, Yuki , KURODA, Akio , TANAKA, Hirokazu
发明人： FUJISAWA PHARMACEUTICAL CO., LTD.
IPC分类号： C07D401/14
CPC分类号： C07D401/14 , C07D471/04 , Y02P20/55
摘要： The object compound of formula (I) wherein R is quinolyl or naphthyridinyl which may have suitable substituent(s), R is hydrogen, halogen, nitro, lower alkyl, lower alkoxy, amino or acylamino, R , R and R are each hydrogen, halogen, nitro, cyano, lower alkyl, lower alkenyl, lower alkylthio, mono or di or trihalo(lower)alkyl, oxo(lower)alkyl, hydroxy(lower)alkyl or optionally esterified carboxy; or R and R are linked together to form 1,3-butadienylene; R is hydrogen or imino-protective group; A is lower alkylene; Q is CH or N; X is N or CH; Y is NH, O or S; and n is 0 or 1; and pharmaceutically acceptable salts thereof which are useful as a medicament.
摘要翻译：式（I）的目标化合物，其中R是可具有合适取代基的喹啉基或萘啶基，R 1是氢，卤素，硝基，低级烷基，低级烷氧基，氨基或酰氨基，R 2，R 低级烷基，低级烷基，低级烷硫基，一或二或三卤代（低级）烷基，氧代（低级）烷基，羟基（低级）烷基或任选地酯化羧基; 或R 2和R 3连接在一起形成1,3-丁二烯; R 5是氢或亚氨基保护基; A是低级亚烷基; Q是CH或N; X为N或CH; Y是NH，O或S; 并且n为0或1; 和其药学上可接受的盐，其可用作药物。

8. 发明申请

WO2006028269A3 THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY 审中-公开
标题翻译：具有VAP-1 IHIBITORY活性的噻唑衍生物
公开(公告)号：WO2006028269A3
公开(公告)日：2006-06-29
申请号：PCT/JP2005016984
申请日：2005-09-08
申请人： ASTELLAS PHARMA INC , INOUE TAKAYUKI , TOJO TAKASHI , MORITA MASATAKA
发明人： INOUE TAKAYUKI , TOJO TAKASHI , MORITA MASATAKA
IPC分类号： C07D417/06 , A61K31/426 , A61K31/427 , A61P27/02 , C07D277/46 , C07D417/10 , C07D417/12
CPC分类号： C07D417/10 , C07D277/46 , C07D417/06 , C07D417/12
摘要： A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is -CONH- or -NR 1 CO- wherein R 1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: (a) wherein R 2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, (b); D is a bond, -CS- or -CO-; E is a bond or -NH-; F is a bond, -CO-, -O- or -SO 2 -; and G is lower alkyl, optionally protected amino, -OH, phenyl, (c); and R 3 is lower alkyl, provided that when Z is a group of the formula: (d), then G should not be amino, when Z is a group of the formula: (e), then G should not be (f), when Z is a group of the formula: (g) and G is optionally protected amino, then D should be -CS-, or then A should be lower alkylene, B or E should be -NH- and F should be -CO-; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
摘要翻译：式（I）的化合物：U-V-W-X-Y-Z（I）其中U是低级烷基; V是-CONH-或-NR 1 CO-，其中R 1是氢或低级烷基; W是键或低级亚烷基; X是衍生自任选取代的噻唑的二价残基; Y是键或低级亚烷基; 并且Z是下式的基团：（a）其中R 2是下列基团：-A-B-D-E-F-G其中A是键或低级亚烷基; B是债券，（b）; D是键，-CS-或-CO-; E是键或-NH-; F是键，-CO - ， - O-或-SO 2 - 。和G是低级烷基，任选保护的氨基，-OH，苯基，（c）; 并且R 3为低级烷基，条件是当Z为式（d）的基团时，则当Z为下列基团时，G不应为氨基，则 G不应该是（f），当Z是下列基团时：（g）和G是任选保护的氨基，那么D应该是-CS-，或者A应该是低级亚烷基，B或E应该是-NH - 和F应为-CO-; 或其药学上可接受的盐可用作血管粘附蛋白-1（VAP-1）抑制剂，以及用于预防或治疗VAP-1相关疾病，特别是黄斑水肿的药物组合物和方法，该方法包括施用有效的化合物或其药学上可接受的盐对受试者的量等。

9. 发明申请

WO2006046683A1 THIAZOLYLBENZOFURAN DERIVATIVES AS LEUKOTRIENE AND PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：噻吗啉衍生物作为白介素和前列腺素D2受体拮抗剂
公开(公告)号：WO2006046683A1
公开(公告)日：2006-05-04
申请号：PCT/JP2005/019854
申请日：2005-10-24
申请人： ASTELLAS PHARMA INC. , SHIGENAGA, Shinji , HIGUCHI, Koichi , MUKOYOSHI, Koichiro , TANABE, Daisuke , INOUE, Takayuki , SATO, Kentaro , TENDA, Yoshiyuki , TSUJIMOTO, Susumu
发明人： SHIGENAGA, Shinji , HIGUCHI, Koichi , MUKOYOSHI, Koichiro , TANABE, Daisuke , INOUE, Takayuki , SATO, Kentaro , TENDA, Yoshiyuki , TSUJIMOTO, Susumu
IPC分类号： C07D417/14 , A61K31/425
CPC分类号： C07D417/14
摘要： There is provided a compound of the formula (I): wherein R 1 is lower alkyl, R 2 is lower alkyl substituted with a substituent selected from the group consisting of carboxy and esterified carboxy, and R 3 is lower alkoxy substituted with lower alkylcarbamoyl, or a pharmaceutically acceptable salt thereof, which are useful as a medicament.
摘要翻译：提供式（I）化合物：其中R 1为低级烷基，R 2为被选自下组的取代基取代的低级烷基：羧基和酯化的羧基，R 3是用作药物的低级烷基氨基甲酰基或其药学上可接受的盐取代的低级烷氧基。

10. 发明申请

WO2006011631A2 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY 审中-公开
标题翻译：具有VAP-1抑制活性的噻唑衍生物
公开(公告)号：WO2006011631A2
公开(公告)日：2006-02-02
申请号：PCT/JP2005014136
申请日：2005-07-27
申请人： ASTELLAS PHARMA INC , INOUE TAKAYUKI , TOJO TAKASHI , MORITA MASATAKA
发明人： INOUE TAKAYUKI , TOJO TAKASHI , MORITA MASATAKA
IPC分类号： C07D277/00
CPC分类号： C07D277/46
摘要： A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification,or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
摘要翻译：式（I），（II），（III）或（IV）的化合物：其中每个符号如说明书中所定义，或其药学上可接受的盐可用作血管粘附蛋白-1（VAP-1）抑制剂，药物组合物，预防或治疗VAP-1相关疾病，特别是黄斑水肿的方法，该方法包括向受试者施用有效量的化合物或其药学上可接受的盐等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式